HIGHLIGHTS
- What: The analysis focused on quantifying patients with leukocytosis (> 10 G/L), differentiation syndrome (DS), and hepatic impairment (notably alanine aminotransferase elevation) within the initial 25 days of treatment.
- Who: Acute promyelocytic leukemia et al. from the National Cancer Institute have published the article: Distinctive Features Associated with Differentiation Syndrome in Acute Promyelocytic Leukemia in Patients treated by All-Trans Retinoic Acid and Arsenic Trioxide, in the Journal: (JOURNAL)
- Future: Page 9/16 While hepatotoxicity is often reported as an adverse effect of arsenic further studies are needed to fully understand the relationship . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.